Department of Orthopedics and Orthopedic Research Center, Kaohsiung Municipal Ta-Tung Hospital and Kaohsiung Medical University Hospital, College of Medicine, Kaohsiung Medical University, Kaohsiung City, Taiwan.
Department of Orthopedic Surgery, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, South Korea.
Clin Interv Aging. 2020 Jan 30;15:111-121. doi: 10.2147/CIA.S228158. eCollection 2020.
The aim of this analysis is to describe the baseline characteristics of patients who are prescribed teriparatide for the treatment of postmenopausal osteoporosis in a real-world setting in East Asia.
The Asia and Latin America Fracture Observational Study (ALAFOS) is a prospective, multinational, observational study designed to evaluate real-world use of teriparatide in the treatment of postmenopausal osteoporosis in 20 countries across Asia, Latin America, the Middle East, and Russia. This subregional analysis focuses on the East Asian subpopulation of the ALAFOS study. Here we report baseline clinical characteristics, details regarding the history of fractures, risk factors for osteoporosis, comorbidities, osteoporosis treatment, and health-related quality of life in patients enrolled in China, Hong Kong, South Korea, and Taiwan.
The East Asian subgroup of ALAFOS included 1136 postmenopausal women, constituting 37.5% (1136/3031) of the overall ALAFOS patient population. The mean (SD) age was 75.0 (9.6) years. The mean (SD) bone mineral density T-scores were -3.11 (1.54), -2.58 (1.11), and -2.86 (1.09) at the lumbar spine, total hip, and femoral neck, respectively; 69.6% of patients had experienced at least one fragility fracture and 40.4% had experienced ≥2 fragility fractures after 40 years of age. Overall, 63.3% of patients had used medications for osteoporosis in the past. The mean (SD) EQ-5D-5L Visual Analog Scale (VAS) score at baseline was 59.7 (20.8); the mean (SD) back pain numeric rating scale score for worst pain in the last 24 hrs was 5.2 (3.2).
Our results indicate that patients who are prescribed teriparatide in East Asia were elderly women with severe osteoporosis, low bone mineral density, high prevalence of fractures, back pain and poor health-related quality of life. Most of the patients received teriparatide as a second-line treatment.
本分析旨在描述在东亚真实环境中接受特立帕肽治疗绝经后骨质疏松症患者的基线特征。
亚洲和拉丁美洲骨折观察研究（ALAFOS）是一项前瞻性、多中心、观察性研究，旨在评估特立帕肽在 20 个亚洲、拉丁美洲、中东和俄罗斯国家治疗绝经后骨质疏松症的真实世界应用。这项亚区域分析侧重于 ALAFOS 研究的东亚亚人群。在这里，我们报告了入组中国、中国香港、韩国和中国台湾的患者的基线临床特征、骨折史详情、骨质疏松症风险因素、合并症、骨质疏松症治疗和健康相关生活质量。
ALAFOS 的东亚亚组包括 1136 例绝经后妇女，占 ALAFOS 总体患者人群的 37.5%（1136/3031）。平均（SD）年龄为 75.0（9.6）岁。平均（SD）骨密度 T 评分分别为腰椎-3.11（1.54）、全髋-2.58（1.11）和股骨颈-2.86（1.09）；69.6%的患者至少经历过一次脆性骨折，40.4%的患者在 40 岁后经历过≥2 次脆性骨折。总体而言，63.3%的患者过去曾使用过骨质疏松症药物。基线时 EQ-5D-5L 视觉模拟量表（VAS）评分的平均值（SD）为 59.7（20.8）；过去 24 小时内最严重背痛的数字评分量表评分平均值（SD）为 5.2（3.2）。
我们的结果表明，在东亚接受特立帕肽治疗的患者为年龄较大的女性，患有严重的骨质疏松症、骨密度低、骨折发生率高、背痛和较差的健康相关生活质量。大多数患者接受特立帕肽作为二线治疗。
